Achievements and Limitations of Complement Inhibition by Eculizumab in Paroxysmal Nocturnal Hemoglobinuria: The Role of Complement Component 3

Publisher： Bentham Science Publishers

E-ISSN： 1875-5607|11|6|528-535

ISSN： 1389-5575

Source： Mini Reviews in Medicinal Chemistry, Vol.11, Iss.6, 2011-06, pp. : 528-535

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Paroxysmal Nocturnal Hemoglobinuria in Children

By Marry M. van den Heuvel-Eibrink

Pediatric Drugs, Vol. 9, Iss. 1, 2007-01 ,pp. : 11-16

Adis International

Access to resources Recommend Favorite

Eculizumab for paroxysmal nocturnal haemoglobinuria

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 513, 2006-01 ,pp. : 9-9

Adis International

Access to resources Recommend Favorite

Eculizumab for paroxysmal nocturnal haemoglobinuria

Inpharma, Vol. 1, Iss. 1557, 2006-01 ,pp. : 8-8

Adis International

Access to resources Recommend Favorite

Eculizumab in Paroxysmal Nocturnal Haemoglobinuria

By Charneski Lisa

Drugs, Vol. 68, Iss. 10, 2008-01 ,pp. : 1341-1346

Adis International

Access to resources Recommend Favorite

A role of complement component C5 in liver regeneration

By Mastellos D. Papadimitriou J.C. Franchini S. Tsonis P.A. Lambris J.D.

Immunopharmacology, Vol. 49, Iss. 1, 2000-08 ,pp. : 8-8

Elsevier

Access to resources Recommend Favorite